| dc.contributor.author | Heward, JA | en_US |
| dc.contributor.author | Kumar, EA | en_US |
| dc.contributor.author | Korfi, K | en_US |
| dc.contributor.author | Okosun, J | en_US |
| dc.contributor.author | Fitzgibbon, J | en_US |
| dc.date.accessioned | 2018-06-11T14:40:00Z | |
| dc.date.issued | 2018-07 | en_US |
| dc.date.submitted | 2018-05-16T11:24:50.099Z | |
| dc.identifier.issn | 1065-6251 | en_US |
| dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/39483 | |
| dc.description.sponsorship | Cancer Research UK (15968
awarded to J.F., 22742 awarded to J.O.) and Bloodwise
program grant [15002] through the Precision Medicine
for Aggressive Lymphoma (PMAL) consortium. E.A.K. is
in receipt of fellowship funding from The Medical College
of Saint Bartholomew’s Hospital Trust. J.F. declares
grants from Epizyme and personal fees from Roche,
Gilead, Janssen and Epizyme. | en_US |
| dc.format.extent | 329 - 334 | en_US |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | CURRENT OPINION IN HEMATOLOGY | en_US |
| dc.rights | All rights reserved. | |
| dc.subject | diffuse large B-cell lymphoma | en_US |
| dc.subject | follicular lymphoma | en_US |
| dc.subject | precision medicine | en_US |
| dc.subject | targeted therapies | en_US |
| dc.title | Precision medicine and lymphoma | en_US |
| dc.type | Article | |
| dc.rights.holder | Wolters Kluwer Health, Inc | |
| dc.identifier.doi | 10.1097/MOH.0000000000000437 | en_US |
| pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000441406700013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
| pubs.issue | 4 | en_US |
| pubs.notes | Not known | en_US |
| pubs.publication-status | Published | en_US |
| pubs.volume | 25 | en_US |
